Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease
Julia Wollenhaupt,
Janina Frisch,
Eva Harlacher,
Dickson W.L. Wong,
Han Jin,
Corinna Schulte,
Sonja Vondenhoff,
Julia Moellmann,
Barbara Mara Klinkhammer,
Li Zhang,
Adelina Baleanu-Curaj,
Elisa A. Liehn,
Thimoteus Speer,
Andrey Kazakov,
Christian Werner,
Emiel P.C. van der Vorst,
Simina-Ramona Selejan,
Mathias Hohl,
Michael Böhm,
Rafael Kramann,
Erik A.L. Biessen,
Michael Lehrke,
Nikolaus Marx,
Joachim Jankowski,
Christoph Maack,
Peter Boor,
Leticia Prates Roma,
Heidi Noels
Affiliations
Julia Wollenhaupt
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Janina Frisch
Department of Biophysics, Center for Integrative Physiology and Molecular Medicine, Medical Faculty, Saarland University, Center for Human and Molecular Biology, Homburg/Saar, Germany
Eva Harlacher
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Dickson W.L. Wong
Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
Han Jin
Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Science for Life Laboratory (SciLifeLab), KTH Royal Institute of Technology, Stockholm, Sweden
Corinna Schulte
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Sonja Vondenhoff
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Julia Moellmann
Department of Internal Medicine I, Cardiology, University Hospital RWTH Aachen, Aachen, Germany
Barbara Mara Klinkhammer
Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
Li Zhang
Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
Adelina Baleanu-Curaj
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany
Elisa A. Liehn
Institute for Molecular Medicine, University of South Denmark, Odense, Denmark; National Institute for Pathology “Victor Babes”, Bucharest, Romania
Department of Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Centre, Homburg/Saar, Germany
Christian Werner
Department of Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Centre, Homburg/Saar, Germany
Emiel P.C. van der Vorst
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany; Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Interdisciplinary Centre for Clinical Research (IZKF), RWTH Aachen University, Aachen, Germany; Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Munich, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
Simina-Ramona Selejan
Department of Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Centre, Homburg/Saar, Germany
Mathias Hohl
Department of Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Centre, Homburg/Saar, Germany
Michael Böhm
Department of Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Centre, Homburg/Saar, Germany
Rafael Kramann
Institute of Experimental Medicine and Systems Biology, University Hospital RWTH Aachen, Aachen, Germany; Department of Nephrology and Clinical Immunology, University Hospital RWTH Aachen, Aachen, Germany; Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, the Netherlands
Erik A.L. Biessen
Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
Michael Lehrke
Department of Internal Medicine I, Cardiology, University Hospital RWTH Aachen, Aachen, Germany
Nikolaus Marx
Department of Internal Medicine I, Cardiology, University Hospital RWTH Aachen, Aachen, Germany
Joachim Jankowski
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany; Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
Christoph Maack
Department of Translational Research, Comprehensive Heart Failure Center (CHFC), University Hospital Würzburg, Germany
Peter Boor
Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany; Department of Nephrology and Clinical Immunology, University Hospital RWTH Aachen, Aachen, Germany
Leticia Prates Roma
Department of Biophysics, Center for Integrative Physiology and Molecular Medicine, Medical Faculty, Saarland University, Center for Human and Molecular Biology, Homburg/Saar, Germany; Corresponding author. Department of Biophysics, Center for Integrative Physiology and Molecular Medicine, Medical Faculty, Saarland University, Center for Human and Molecular Biology, Homburg/Saar, Germany.
Heidi Noels
Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Corresponding author. Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Pauwelsstraße 30, 52074, Germany.
Aims: Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular events and exhibit myocardial changes including left ventricular (LV) hypertrophy and fibrosis, overall referred to as ‘uremic cardiomyopathy’. Although different CKD animal models have been studied for cardiac effects, lack of consistent reporting on cardiac function and pathology complicates clear comparison of these models. Therefore, this study aimed at a systematic and comprehensive comparison of cardiac function and cardiac pathophysiological characteristics in eight different CKD models and mouse strains, with a main focus on adenine-induced CKD. Methods and results: CKD of different severity and duration was induced by subtotal nephrectomy or adenine-rich diet in various strains (C57BL/6J, C57BL/6 N, hyperlipidemic C57BL/6J ApoE−/−, 129/Sv), followed by the analysis of kidney function and morphology, blood pressure, cardiac function, cardiac hypertrophy, fibrosis, myocardial calcification and inflammation using functional, histological and molecular techniques, including cardiac gene expression profiling supplemented by oxidative stress analysis. Intriguingly, despite uremia of variable degree, neither cardiac dysfunction, hypertrophy nor interstitial fibrosis were observed. However, already moderate CKD altered cardiac oxidative stress responses and enhanced oxidative stress markers in each mouse strain, with cardiac RNA sequencing revealing activation of oxidative stress signaling as well as anti-inflammatory feedback responses. Conclusion: This study considerably expands the knowledge on strain- and protocol-specific differences in the field of cardiorenal research and reveals that several weeks of at least moderate experimental CKD increase oxidative stress responses in the heart in a broad spectrum of mouse models. However, this was insufficient to induce relevant systolic or diastolic dysfunction, suggesting that additional “hits” are required to induce uremic cardiomyopathy. Translational perspective: Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular adverse events and exhibit myocardial changes, overall referred to as ‘uremic cardiomyopathy’. We revealed that CKD increases cardiac oxidative stress responses in the heart. Nonetheless, several weeks of at least moderate experimental CKD do not necessarily trigger cardiac dysfunction and remodeling, suggesting that additional “hits” are required to induce uremic cardiomyopathy in the clinical setting. Whether the altered cardiac oxidative stress balance in CKD may increase the risk and extent of cardiovascular damage upon additional cardiovascular risk factors and/or events will be addressed in future studies.